Genscript BiotechHKSE:01548 -0.74%74 Operating Margin % is 18.11% as of Dec. 2025, which is 377% above its 10-year median of 3.80. GuruFocus rates HKSE:01548 with a GF Score™ of 74/100 and a GF Value™ of HK$21.17 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 942 Biotechnology companies, Genscript Biotech ranks better than 92.25% on this metric.
The historical rank and industry rank for Genscript Biotech's Operating Margin % or its related term are showing as below:
HKSE:01548'
s Operating Margin % Range Over the Past 10 Years
Min: -75.33 Med: 3.8 Max: 28.73
Current: 27.36
HKSE:01548's Operating Margin % is ranked better than 92.25% of 942
companies
in the Biotechnology industry
Industry Median: -86.83
vs HKSE:01548: 27.36
Genscript Biotech's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Genscript Biotech Operating Margin % Related Terms
Genscript Biotech Operating Margin % Historical Data
* Premium members only.
The historical data trend for Genscript Biotech's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:01548 vs VRTX, REGN, ALNY: Operating Margin % Comparison
For the Biotechnology subindustry, Genscript Biotech's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genscript Biotech Operating Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genscript Biotech's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Genscript Biotech's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Genscript Biotech's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genscript Biotech (HKSE:01548) has a Operating Margin % of 18.11% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Genscript Biotech and its competitors. This is 377% above median its historical median of 3.80. According to the industry distribution chart, Genscript Biotech ranks #73 out of 942 companies in the Biotechnology industry, placing it in the top 7.7%.
Is Genscript Biotech's Operating Margin % too high?
Genscript Biotech's current Operating Margin % of 18.11% is 377% above median its 10-year median of 3.80. Based on the distribution chart, Genscript Biotech ranks #73 out of 942 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genscript Biotech has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genscript Biotech's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genscript Biotech ranks #73 out of 942 companies for Operating Margin %. This places Genscript Biotech in the top 8% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Genscript Biotech and its competitors. Genscript Biotech's current Operating Margin % is 18.11%, which is 377% above median its own 10-year median of 3.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genscript Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genscript Biotech (HKSE:01548) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$21.17, compared to a current price of HK$12.10 — trading 42.8% below its estimated fair value. The current Operating Margin % is 18.11%, which is 377% above median its 10-year median of 3.80. Genscript Biotech's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Genscript Biotech (HKSE:01548), the current Operating Margin % is 18.11% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genscript Biotech (HKSE:01548) Overvalued in 2026?
Based on GuruFocus' analysis, Genscript Biotech stock appears to be undervalued.
The current stock price of HK$12.10 is trading 42.8% below its estimated GF Value™ of HK$21.17.
GuruFocus considers Genscript Biotech to be Significantly Undervalued.
Key valuation signals for HKSE:01548:
Operating Margin %: 18.11% (377% above median its 10-year median of 3.80)
GF Value™: HK$21.17 vs. price of HK$12.10 (42.8% below fair value)
No single metric tells the full story. See the HKSE:01548 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GenScript Biotech Corp is an investment holding company engaged in the manufacture and sale of life science research products and services, including life science services and products, biologics development services, and industrial synthetic biology products. Its segments include life science services and products, which generate maximum revenue and provide research services and products; biologics development services, which support the development of therapeutic antibodies and CGT products; industrial synthetic biology, which provides enzyme development and production using engineered microbial strains; and the operation unit, which provides shared services. It operates in Mainland China, which generates maximum revenue, U.S., Europe, and the Asia Pacific excluding Mainland China.
74GF Score
Get the complete analysis for HKSE:01548
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01548 has been successfully added to your 
